NASDAQ: LXEO - Lexeo Therapeutics, Inc.

Altı ay boyunca karlılık: -54.65%
Temettü getirisi: 0.00%
Sektör: Healthcare

Promosyon programı Lexeo Therapeutics, Inc.

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında Lexeo Therapeutics, Inc.

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations.

daha fazla ayrıntı
It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

IPO date 2023-11-03
ISIN US52886X1072
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.lexeotx.com
Цена ао 3.99
Günlük fiyat değişimi: -0.2433% (4.11)
Haftalık fiyat değişimi: +51.29% (2.71)
Aylık fiyat değişimi: +29.75% (3.16)
3 ayda fiyat değişimi: -39.53% (6.78)
Altı ayda fiyat değişimi: -54.65% (9.04)
Yıllık fiyat değişimi: -73.85% (15.68)
Yılbaşından bu yana fiyat değişimi: -37.69% (6.58)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 0 0
P/BV 3.15 5
P/E 0 0
EV/EBITDA -3.72 0
Toplam: 3.13

Yeterlik

İsim Anlam Seviye
ROA, % -47.49 0
ROE, % -58.48 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA -0.1746 10
Toplam: 9.4

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % 26.25 4
karlılık Ebitda, % 1349.35 10
karlılık EPS, % 1092.76 10
Toplam: 8.8
Daha fazla ayrıntı

Kurumlar Hacim Paylaşmak, %
Artal Group S.A. 603435 2.26
Citigroup Inc. 91889 0.34
Bank Of New York Mellon Corporation 14110 0.05
Wells Fargo & Company 72 0

ETFPaylaşmak, %Yıllık karlılık, %Temettüler, %
iShares Micro-Cap ETF 0.06431 17.09 1.54048
iShares Russell 2000 Growth ETF 0.01747 38.04 0.6026
0.0427.571.07



Süpervizör İş unvanı Ödeme Doğum yılı
Mr. R. Nolan Townsend CEO & Director 864.34k 1981 (44 yıl)
Dr. Ronald G. Crystal M.D. Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board N/A
Dr. Eric Adler M.D. Chief Medical Officer & Head of Research 623.4k 1974 (51 yıl)
Dr. Sandi See Tai M.D. Chief Development Officer N/A 1971 (54 yıl)
Mr. Ryan McHenry VP & Corporate Controller N/A
Ms. Jenny R. Robertson J.D. Chief Business & Legal Officer 617.9k 1975 (50 yıllar)
Mr. Rand Monaghan Vice President of Finance
Dr. Jose Manuel Otero Ph.D. Chief Technical Officer

Adres: United States, New York. NY, 345 Park Avenue South - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.lexeotx.com